Munhu EML4-ALK Fusion Gene Mutation

Kiti iyi inoshandiswa kuona zvine mutsindo mhando gumi nembiri dzeEML4-ALK fusion gene mumasampuli evarwere vekenza yemapapu emunhu asiri diki.Mhedzisiro yebvunzo ndeyekuongororwa kwekiriniki chete uye haifanirwe kushandiswa seyo chete hwaro hwekurapwa kwega kwevarwere.Varapi vanofanira kuita mutongo wakakwana pamusoro pezvabuda pabvunzo zvichibva pazvinhu zvakaita semamiriro emurwere, zviratidzo zvemushonga, mhinduro yekurapwa, uye zvimwe zviratidzo zvemurabhoritari.Chirwere chegomarara remapapu ndiro rinonyanya kurwara nechirwere chegomarara pasi rese, uye 80% ~ 85% yemakesi isiri-diki cell lung cancer (NSCLC).Gene fusion ye echinoderm microtubule-associated protein-like 4 (EML4) uye anaplastic lymphoma kinase (ALK) inyaya inotariswa muNSCLC, EML4 neALK zvakateerana inowanikwa mumunhu mabhendi eP21 neP23 pakromosome 2 uye akapatsanurwa neanenge 12.7 miriyoni base pairs.Anosvika makumi maviri akasiyana emusanganiswa awanikwa, pakati pawo gumi nemaviri ekuchinjanisa ari muTebhurari 1 akajairika, apo mutant 1 (E13; A20) ndiyo inonyanya kuwanda, ichiteverwa nema mutants 3a uye 3b (E6; A20), inoverengera nezve. 33% uye 29% yevarwere vane EML4-ALK fusion gene NSCLC, maererano.ALK inhibitors inomiririrwa neCrizotinib madiki-morekuru anonangwa zvinodhaka zvakagadzirirwa ALK gene fusion mutations.Nekuvharidzira kuita kwenzvimbo yeALK tyrosine kinase, ichivharira nzira dzayo dzezasi dzechiratidzo, nekudaro zvichitadzisa kukura kwemamota maseru, kuwana kurapa kwakanangwa kwemamota.Zvidzidzo zvekiriniki zvakaratidza kuti Crizotinib ine mwero unoshanda weanopfuura 61% muvarwere vane EML4-ALK fusion mutations, nepo isingaite mhedzisiro yevarwere vesango.Nokudaro, kuonekwa kweEML4-ALK fusion mutation ndiyo nheyo uye nheyo yekutungamirira kushandiswa kwemishonga yeCrizotinib.